`Filed July 8, 2016
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`_____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`_____________________
`
`
`
`
`
`APOTEX INC. and APOTEX CORP.
`
`Petitioners
`
`V.
`
`ELI LILLY & COMPANY
`
`Patent Owner
`
`_____________________
`
`U.S. Patent No. 7,772,209
`Filed: July 11, 2007
`Issued: August 10, 2010
`Inventor: Clet Niyikiza
`
`TITLE: ANTIFOLATE COMBINATION THERAPIES
`
`_____________________
`
`Inter Partes Review No.: IPR2016-01191
`
`————————————————
`
`UPDATED MANDATORY NOTICE
`
`
`
`IPR2016-01191
`
`Pursuant to 37 C.F.R. § 42.8(a)(3), Petitioners Apotex Inc. and Apotex Corp.
`
`(“Apotex”), hereby submit this Updated Mandatory Notice of related matters per
`
`37 C.F.R. § 42.8(b)(2), to supplement the notice of related matters in the Petition:
`
`• Petition for IPR by Teva Pharmaceuticals USA, Inc., PTAB-IPR2016-
`
`01340 (filed July 1, 2016);
`
`• Petition for IPR by Teva Pharmaceuticals USA, Inc., PTAB-IPR2016-
`
`01341 (filed July 1, 2016); and
`
`• Petition for IPR by Teva Pharmaceuticals USA, Inc., PTAB-IPR2016-
`
`01343 (filed July 1, 2016).
`
`July 8, 2016
`
`
`
`Respectfully submitted,
`
`/John D. Polivick/
`John D. Polivick (Reg. No. 57,926)
`jpolivick@rmmslegal.com
`Rakoczy Molino Mazzochi Siwik LLP
`6 West Hubbard Street, Suite 500,
`Chicago, Illinois 60654
`Tel. 312-222-5127
`
`
`
`
`
`
`
`
`1
`
`
`
`IPR2016-01191
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that on July 8, 2016, a copy of this Updated Mandatory
`
`Notice was served via U.S.P.S. Priority Mail Express, upon the following:
`
`Elizabeth A. McGraw
`Eli Lilly and Company
`Patent Division
`P.O. Box 6288
`Indianapolis, Indiana 46206-6288
`
`
`And electronically on:
`
`
`Dov P. Grossman
`Williams & Connolly, LLP
`725 12th St., NW
`Washington, DC 20005
`
`dgrossman@wc.com
`dkrinsky@wc.com
`leeds_james@lilly.com
`
`Lead Counsel for Eli Lilly & Company in IPR2016-00240
`
`
`Dated: July 8, 2016
`
`/John D. Polivick/
` Telephone: (312) 222-6305
` Facsimile: (312) 222-6325
`
`
`
`
`2